After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The company sans CEO Scangos needs to do some type of deal in the coming months.
Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.